Key Takeaways
- Do not wait until the next scheduled visit to mention a new symptom, emergency visit, hospital admission, medication change, pregnancy or device problem. Use the contact and timing rules in the consent form and participant card.
- “Serious” describes an outcome such as death, a life-threatening event, hospital admission, substantial disability or a medically important event. It is not the same as “severe,” which describes intensity [1,5].
- A participant reports facts. The investigator and sponsor assess severity, seriousness, causality and expectedness; the participant does not need to prove that the study caused the event.
- In an emergency, obtain local medical care first. Tell the treating team about trial participation, then notify the study site as soon as possible.
- Reporting an event does not automatically mean leaving the trial. Treatment may continue, pause, change or stop after a clinical and protocol-based review.
Content
A participant develops a fever on a Saturday, is admitted to a hospital near home and assumes the clinical-trial team will see the record automatically. It often will not. Another participant says nothing about numb fingers because the consent form already listed neuropathy. That information still matters: a known reaction can become more intense, last longer, prompt a dose change or appear in a pattern that changes the study’s risk–benefit assessment.
Safety reporting begins with a short practical rule: tell the study team what happened, when it happened and what care you received. Do not decide first whether it “counts.”
Emergency care comes before research paperwork
Call local emergency services or go to the nearest emergency department for severe breathing difficulty, chest pain, signs of stroke, loss of consciousness, uncontrolled bleeding, a severe allergic reaction, suicidal thoughts or another urgent condition. Do not delay treatment while waiting for a coordinator in another city or time zone.
Show the treating clinician the trial participant card or the consent-page contacts. It should identify the investigational product or device, principal investigator/site, emergency contact and, where relevant, precautions such as immune toxicity, bleeding risk, infection risk, implanted hardware or restrictions on concomitant treatment. If the card is incomplete, ask the site to correct it before the first dose or procedure.
Once immediate care is under way, the participant or companion should contact the study site. Ask the local hospital to preserve the emergency note, medication administration record, laboratory and imaging results, admission/discharge summary and final diagnosis. These records help the investigator understand the event without asking the local clinician to reconstruct it later.
Patient notification and regulatory reporting are different jobs
The participant’s job is to notify the authorised study contact. The site then documents and medically assesses the event. For most serious adverse events, China’s currently effective 2020 drug GCP requires the investigator to report promptly to the sponsor, followed by a detailed written follow-up; the sponsor evaluates seriousness, relatedness and expectedness and handles required safety communications [1]. China’s drug-registration rules place continuing safety-risk responsibility on the sponsor and allow protocol changes, suspension or termination when safety requires it [2].
The CDE receives rapid reports of suspected unexpected serious adverse reactions (SUSARs), other potentially serious safety risks and annual development safety update reports through its clinical-development safety system [3]. A participant ordinarily does not submit those sponsor reports personally.
The exact pathway differs for drugs, devices, investigator-initiated studies and non-interventional research. China’s 2022 device GCP separately defines adverse events, serious adverse events and device defects and assigns reporting and risk-control duties to investigators, institutions and sponsors [4]. Follow the consent form and site instructions for the actual study rather than borrowing deadlines from another protocol.
Four labels answer four different questions
Label · Question it answers · Patient-facing example
Adverse event (AE) · Did an unfavourable medical event occur during the protocol’s collection period? · rash, abnormal liver test, fall, infection or worsening disease; it need not be caused by the study product
Severity · How intense was it? · mild nausea versus vomiting that prevents eating
Seriousness · Did it cause a defined major outcome or require intervention to prevent one? · hospital admission, life-threatening anaphylaxis, persistent disability or death
Relatedness/causality · Is there a reasonable possibility the intervention contributed? · assessed from timing, mechanism, alternatives, dechallenge/rechallenge and other evidence
Expectedness · Is its nature or severity consistent with the reference safety information? · assessed against the investigator’s brochure or other designated safety reference
A headache can be severe without being “serious” under the regulatory definition. A medically important rhythm disturbance can be serious even if it resolves before admission. The terms are not a ranking of whether the participant deserves care.
A SUSAR requires three elements—suspected, unexpected and serious—and is a sponsor/regulatory classification, not a label the participant must determine. ICH E6(R3) requires sponsors to review accumulating safety information and rapidly report reactions meeting those criteria under applicable rules [5].
What should be reported between visits?
Use the study’s reporting window, but err on the side of notifying the site about:
- new or worsening symptoms, even if listed in the consent form;
- fever, infection, bleeding, falls, seizures, allergic symptoms or new pain;
- an emergency visit, observation stay, admission, operation or extension of an existing admission;
- a new diagnosis, clinically significant abnormal test or death;
- new prescription, over-the-counter medicine, traditional medicine, supplement, vaccine or recreational substance;
- missed, extra or incorrect study doses; accidental exposure; overdose; medication error; or product taken by someone else;
- pregnancy of a participant or partner when the protocol requires it, breastfeeding or a contraception failure;
- a device alarm, breakage, mislabelling, software problem, use error or malfunction—even when no injury occurred;
- an exposure that the protocol identifies as an adverse event of special interest (AESI);
- inability to follow required visits, tests, diet, activity or contraception because of illness;
- a symptom that started after treatment stopped or after withdrawal if it falls within safety follow-up.
Not every item is legally an AE. Pregnancy, overdose without symptoms, a near-miss device defect or a protocol deviation may use a different form, but the study team still needs to know. Do not omit cancer progression, an accident or seasonal infection because it seems unrelated: causality comes after fact collection.
Send a timeline, not a diagnosis guess
A useful first message contains:
- participant code, study title/protocol and current location;
- event in plain language and the exact or best-estimated start date/time;
- current status—resolved, improving, unchanged, worsening or unknown;
- last study dose/procedure and recent dose changes;
- other medicines or exposures before the event;
- emergency visit or admission details, including hospital and clinician contact;
- tests, treatment and outcome known so far;
- whether a dose is due before the site can respond;
- a safe return number and preferred language.
Do not send a vague message such as “I had a reaction” and then wait. But do not postpone the initial alert while collecting a perfect file. Send the available facts, label gaps as unknown and provide follow-up documents later. Safety reports are expected to evolve.
Keep a small event log with dates, symptom intensity, temperature or other relevant measurements, actions taken and photographs when clinically useful. Preserve original-language records. A translation helps the Chinese site, but it should not replace the source report or alter dates, diagnoses and units.
What happens after the site receives the report?
The investigator or delegated qualified clinician should first address medical care, then document the event and assess its intensity, seriousness, relationship, expectedness and outcome. China GCP makes the investigator or authorised clinician responsible for trial-related medical decisions and requires appropriate treatment and truthful information for trial-related adverse events, including clinically significant laboratory abnormalities [1].
The sponsor reviews the individual report alongside events from other participants, preclinical findings and product-quality information. It may request missing records, change monitoring, pause dosing, amend eligibility, revise the investigator’s brochure or consent form, notify other sites and ethics committees, or suspend the study. An independent data monitoring committee may review unblinded aggregate data, but it does not replace the investigator’s immediate care duty.
Routine AEs, SAEs, AESIs, pregnancies and device deficiencies may travel through separate workflows. That is why a coordinator may ask similar questions more than once. Ask which person is collecting clinical follow-up and which person handles administrative documents so that nothing falls between teams.
Outside hospitals need enough information to treat safely
An emergency physician does not need permission from the trial sponsor to provide necessary care. Give the physician the product name/code, last dose, known key risks and investigator contact. Do not refuse imaging, antibiotics, surgery or another urgent intervention solely to “protect the protocol.” The treating clinician and investigator can discuss contraindications and protocol consequences once the patient is stable.
If an outside hospital admits the participant, notify the study team of admission and discharge dates, level of care, principal diagnosis and important treatments. Admission for convenience or a protocol-planned procedure may not meet the protocol’s SAE definition; an unplanned admission often does. The investigator, not the participant, makes that determination.
Blinding should be broken only for a clinical reason
In a blinded trial, knowing whether the participant received active treatment may sometimes change urgent care. The site should use the protocol’s emergency-unblinding procedure and document who requested it, why and when. Curiosity, insurance paperwork or a non-urgent side-effect question is not usually enough to unblind. Necessary treatment should not wait for unblinding when the same care is indicated either way.
Pregnancy and reproductive events follow a dedicated plan
Pregnancy is not automatically an adverse event, but most interventional protocols require immediate notification because exposure, contraception and fetal/infant follow-up may matter. Do not make a pregnancy decision on a coordinator’s instruction. Obtain obstetric care and discuss study-drug interruption with an authorised study physician. Partner pregnancy reporting requires the pregnant person’s consent before the study collects identifiable medical information.
The consent form should state the follow-up period, what information will be requested, and how maternal, fetal and infant privacy is protected. A congenital anomaly or other serious outcome may trigger SAE reporting.
Withdrawal does not erase a safety event
A participant may withdraw from treatment or from the study, but the team may still need to resolve an event that began during the reporting period. Clarify separately:
- stopping the investigational intervention;
- stopping protocol visits;
- allowing phone or record-based safety follow-up;
- allowing already collected data and samples to remain in the analysis.
Consent choices and applicable rules determine what can continue. Do not assume that withdrawing means the site should discard a hospitalisation or stop asking whether it resolved. Conversely, follow-up requests should stay within the consented/legal scope.
International participants need a two-country handover
Before leaving China, obtain a 24-hour serious-event number, routine contact, principal investigator/site name, protocol number, participant code, intervention and last dose, reporting end date, expected follow-up schedule and permission route for record exchange. Test the number once and record the time-zone difference.
Nominate a clinician at home, with consent, to communicate with the Chinese investigator. Agree who will:
- provide emergency care;
- decide on the next study dose;
- order and interpret follow-up tests;
- translate and transmit records securely;
- pay initially and submit claims;
- tell both teams when the event resolves or changes.
The local clinician treats the patient; the trial investigator remains responsible for study assessment and reporting. Neither should assume the other has completed the task.
New safety information should return to participants
If accumulated reports reveal a material new risk, the sponsor and investigator may update monitoring, consent or treatment. ICH E6(R3) says emerging information that could affect willingness to continue should be communicated in a timely way to participants and relevant oversight bodies [5]. China’s 2023 ethics measures likewise centre the participant’s rights, health and dignity and require continuing ethics oversight [6].
Ask three questions when a new safety letter arrives: What changed? Does it change my personal risk or alternatives? Is re-consent or a treatment decision needed before the next procedure? Signing an updated form should not replace that conversation.
China published a revised drug GCP in 2026 that will take effect on 1 September 2026, replacing the 2020 version [7]. Studies spanning the transition should explain which updated procedures apply; the participant’s instruction card and consent contacts should remain operational throughout.
A pre-dose safety check worth doing
- Save the daytime and 24-hour numbers in two phones.
- Photograph the participant card and keep a printed copy.
- Confirm which events require same-day contact and which can wait for a diary/visit.
- Ask what to do if a dose is due while symptoms are being assessed.
- Give the site a complete medication and supplement list.
- Identify the nearest emergency department at home and while travelling.
- Confirm the safety follow-up end date, including after withdrawal.
- Ask how trial-related injury care and reimbursement/compensation claims are documented; do not confuse reimbursement with a promise that the sponsor accepts causality.
Medical disclaimer: This guide explains reporting workflow and does not diagnose an event or replace emergency care, the protocol, consent form or advice from the authorised investigator. In urgent illness, seek local medical treatment first.
FAQ
Should I report a symptom that is already listed as a known side effect?
Yes. Its timing, intensity, duration and effect on dosing may still matter. Follow the protocol’s contact instructions rather than waiting for the next visit.
Does reporting an SAE mean the study drug caused it?
No. Seriousness describes the outcome. Causality is assessed separately by the investigator and sponsor using all available evidence.
What if I am admitted to a hospital outside China?
Obtain necessary care, show the participant card, notify the Chinese site promptly and send the admission/discharge records, medication record, important tests and a local clinician contact through the approved secure channel.
Can I take the next study dose while waiting for a reply?
Do not guess. Use the protocol’s urgent contact or backup number. If you cannot reach the site and are acutely ill, seek local care and show the study information; emergency treatment comes first.
Can I withdraw after an adverse event?
Yes, participation is voluntary. Ask the team to separate stopping treatment from optional safety follow-up and explain what event information still needs to be completed under the consent and applicable rules.
Sources
- China Drug Good Clinical Practice (2020, effective at review date)
- NMPA/CDE — Provisions for Drug Registration
- NMPA Center for Drug Evaluation — Clinical-Trial Safety Information Reporting and Management
- NMPA and National Health Commission — Good Clinical Practice for Medical Device Trials (2022)
- ICH — E6(R3) Good Clinical Practice, Final Guideline
- National Health Commission of China — Ethical Review Measures for Life-Science and Medical Research Involving Humans
- China Drug Good Clinical Practice (2026 revision, effective 1 September 2026)
- NIAMS/NIH — Reportable Events Requirements and Safety Assessment Fields
Image Review
- Decision: Replaced with a topic-specific ImageGen hero and visually reviewed for medical relevance, obvious generation artifacts and bilingual reuse.
- Editorial note: The existing image shows a friendly routine reception conversation but no symptom timeline, urgent contact, participant card, external-hospital handover or safety-reporting action. A replacement should show a participant or companion contacting the study team while a concise event timeline and emergency records are being handed over, without readable health data, distress or regulatory logos.